Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05989308 · ClinicalTrials.gov registry record · NA
MyChart Proxy Outreach to Parents (MyPOP)
A NA study of Health Technology, sponsored by Yale University.
- Recruiting
- Registry status
- NA
- Development phase
- 5,200
- Enrollment target
- 4
- Study locations
NCT05989308: Recruiting NA study of Health Technology, sponsored by Yale University.
NCT05989308 is a NA study of Health Technology that is actively recruiting participants, run by Yale University. The registered enrollment target is 5,200 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (270% higher). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05989308, a NA study of Health Technology, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- NA
- Development phase
- 5,200 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this randomized controlled trial is to assess the extent to which different modes of contacting parents who have not yet enabled to access to their children's medical records will result in greater proxy access. The main questions the study aims to answer are: * will outreach via text or patient portal message result in more parents having access than usual care (which is in-office suggestions to get access). * which mode - text or portal - will get more parents access. Participants will get a text message, or a portal message through their own patient portal, or no message. The investigators will check access to see which group has increased more during the study period.
Primary Outcome
Proportion of participants who activate access to the patient portal of the child's EHR, also known as MyChart Proxy Access, of all those invited. Proxy MyChart activation is a binary function (yes, has proxy activated; no, does not have proxy activated).
Conditions Studied
Interventions
- BEHAVIORAL Email
- BEHAVIORAL Text
- BEHAVIORAL Patient Portal Message
Study Locations (4)
Connecticut
- Cornell Scott Hill Health Center - New Haven
- Fair Haven Community Health Center - New Haven
- Yale New Haven Health - New Haven
- Yale School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,200 participants |
| Start Date | 2024-10-15 |
| Est. Completion | 2026-09 |
| Phase | NA |
What NCT05989308 shows while recruiting
NCT05989308 is an interventional study that assigns participants to a tested intervention. Its 5,200 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (270% higher).
The record links to 1 condition, with Health Technology appearing as the primary indexed condition, and to 3 interventions - of which Email is the first listed.
NCT05989308 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05989308 about?
NCT05989308 is a clinical study titled "MyChart Proxy Outreach to Parents (MyPOP)". The goal of this randomized controlled trial is to assess the extent to which different modes of contacting parents who have not yet enabled to access to their children's medical records will result in greater proxy access. The main questions the study aims to answer are: * will outreach via text o...
What is the current status of trial NCT05989308?
This trial is currently recruiting. It is a NA study. The enrollment target is 5,200 participants. The study started on 2024-10-15. Estimated completion is 2026-09.
What conditions does trial NCT05989308 study?
This clinical trial studies the following conditions: Health Technology.
What interventions are being tested in trial NCT05989308?
The interventions under investigation include: Email (BEHAVIORAL), Text (BEHAVIORAL), Patient Portal Message (BEHAVIORAL).
Who is sponsoring clinical trial NCT05989308?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05989308 being conducted?
This trial has 4 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05989308's enrollment target sits among peer trials
5,200 25th of 2000 higher than 1,976 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06008197 · 5,200 participants · Phase 3
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
- NCT05135403 · 5,179 participants
ASSURE WCD Clinical Evaluation - Post Approval Study (ACE-PAS)
- NCT06506344 · 5,250 participants · NA
Syncing Screening and Services for Suicide Prevention Across Health and Justice Systems
- NCT06535867 · 5,122 participants
The Efficacy of Conventional Screening Versus mHealth Screening in Early Detection of Oral Potentially Malignant Disorders and Oral Cancer Amongst the Rural Population of Varanasi: A Prospective and Blinded Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI